Other diagnosis techniques, such as genomic based liquid biopsies, are unsuitable for most conditions outside of oncology, and incur high costs for population-wide screening.
MetaSight develops and deploys accurate, affordable, and accessible diagnostics for diverse diseases through a single blood test – applicable for population scale screening.
Our approach leverages the world’s largest clinico multi-OMICS database, generated using our proprietary unbiased metabolomics, lipidomics, and proteomics platform.